There has been a big developement last week . Dendreon pulled...

There has been a big developement last week . Dendreon pulled out of the Rodman and Renshaw conference at the last moment leaving their shareholders somewhat puzzled , now they have come out with the info that Dendreons 9901 Provenge vaccine trial against prostrate cancer has drifted into statistical significance , through the secondary median survival endpoint , across all Gleason scores .This trial had been rejected by the FDA for just failing to meet the primary end points in patients due to poor reactions against Gleason scores above 8 . They had started a second Ph3 trial 9902b . Now they are talking about the 9902b being used to confirm only , and it is stacked in such a way (a greater proportion of patients with Gleason scores below 8) as to assure a better result .
It seems that once patients reached disease progression they were allowed to changeover to Provenge , so effectively the Provenge was comparing with itself for survival . That it has now proved significance through the secondary endpoint , shows also that the earlier the vaccine is used , the better the results . They have reached survival rates never seen in advanced prostrate cancer , and the clock is still running for most .
This is the first cancer vaccine , as far as I know , to reach FDA approved end points in a phase 3 trial . Shares jumped 20% overnight .
Did I mention that I suspect Coramsine(SBP002)is ideal for use with vaccines , in that it causes little harm to the TCells and even starts an immune reaction of its own .
cheers